Marcus Schmitt-Egenolf

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4243346/publications.pdf

Version: 2024-02-01

		257357	223716
64	2,253	24	46
papers	citations	h-index	g-index

65	65	65	2359
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence and incidence of generalized pustular psoriasis in Sweden: a populationâ€based register study*. British Journal of Dermatology, 2022, 186, 970-976.	1.4	27
2	Severity of psoriasis â€“ Time to disentangle severity from symptom control. British Journal of Dermatology, 2022, , .	1.4	0
3	Diverse research designs are needed for population health: Lessons from Maslow. Lifestyle Medicine, 2022, 3, .	0.3	0
4	Perception of information to Swedish melanoma patients in routine clinical practice â€“ a cross-sectional survey. BMC Cancer, 2022, 22, 159.	1.1	1
5	Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study. Psoriasis: Targets and Therapy, 2022, Volume 12, 89-98.	1.2	8
6	Complete skin clearance and beyond. British Journal of Dermatology, 2021, 184, 3-4.	1.4	3
7	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
8	Prevalence and incidence of palmoplantar pustulosis in Sweden: a populationâ€based register study*. British Journal of Dermatology, 2021, 185, 945-951.	1.4	8
9	Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. Dermatology and Therapy, 2021, 11, 2107-2121.	1.4	22
10	Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology, 2021, Volume 13, 1141-1153.	1.5	13
11	Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, healthâ€related quality of life improvements and implications for treatment goals. British Journal of Dermatology, 2020, 182, 965-973.	1.4	26
12	Healthâ€related quality of life in patients with melanoma â€“ characterization of a Swedish cohort. British Journal of Dermatology, 2020, 182, 506-508.	1.4	2
13	Paediatric infections in the first 3 years of life after maternal antiâ€TNF treatment during pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 52, 843-854.	1.9	25
14	Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study. JAMA Dermatology, 2020, 156, 795.	2.0	15
15	Antiâ€TNF treatment during pregnancy and birth outcomes: A populationâ€based study from Denmark, Finland, and Sweden. Pharmacoepidemiology and Drug Safety, 2020, 29, 316-327.	0.9	43
16	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€“ Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	1.3	149
17	What can we learn from â€˜dropoutsâ€™ in clinical trials?. British Journal of Dermatology, 2018, 178, 318-319.	1.4	0
18	ä½¿ç”¨ç‚‰©ç——æ³•æ²»ç——é“¶å±‘ç—…çš„æŒç»-PASIâ€ÐLQI åŠ EQâ€5D ç»“æžœ:åŸºäºŽç‘žå…¸å›½å®¶é“¶å±‘ç—……ç™»è®°çš„å¹´ç		

#	Article	IF	Citations
19	Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQolâ€5D response of biological treatment in psoriasis: 10 years of realâ€world data in the Swedish National Psoriasis Register. British Journal of Dermatology, 2018, 178, 245-252.	1.4	17
20	Patient Registries for Safetyness. Methods in Pharmacology and Toxicology, 2018, , 149-164.	0.1	1
21	Real-world outcomes in 2646 psoriasis patients: one in five has PASI â‰¥10 and/or DLQI â‰¥10 under ongoing systemic therapy. Journal of Dermatological Treatment, 2017, 28, 500-504.	1.1	7
22	Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients. BioDrugs, 2017, 31, 75-82.	2.2	14
23	Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. American Journal of Clinical Dermatology, 2017, 18, 583-590.	3.3	99
24	How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health and Quality of Life Outcomes, 2017, 15, 151.	1.0	16
25	Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S , which Encode Subcomponents C1r and C1s of Complement. American Journal of Human Genetics, 2016, 99, 1005-1014.	2.6	100
26	Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. BioDrugs, 2016, 30, 145-151.	2.2	12
27	Physical activity and lifestyle improvement in the management of psoriasis. British Journal of Dermatology, 2016, 175, 452-453.	1.4	7
28	Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. British Journal of Dermatology, 2016, 174, 579-587.	1.4	25
29	The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis. Value in Health, 2015, 18, A675.	0.1	1
30	Hair shaft structures in EDAR induced ectodermal dysplasia. BMC Medical Genetics, 2015, 16, 79.	2.1	5
31	Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. BioDrugs, 2015, 29, 389-398.	2.2	10
32	Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden. Acta Dermato-Venereologica, 2015, 95, 156-161.	0.6	12
33	Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent. Dermatology, 2015, 230, 347-353.	0.9	8
34	Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (<scp>PASI</scp>) than with the Dermatology Life Quality Index (<scp>DLQI</scp>). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 452-456.	1.3	38
35	Health-Care Delay in Malignant Melanoma: Various Pathways to Diagnosis and Treatment. Dermatology Research and Practice, 2014, 2014, 1-6.	0.3	11
36	EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072Câ€‰>â€‰T mutation. BMC Medical Genetics, 2014, 15, 57.	2.1	9

#	Article	IF	Citations
37	Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. British Journal of Dermatology, 2013, 169, 710-714.	1.4	19
38	Coping styles in decision-making among men and women diagnosed with malignant melanoma. Journal of Health Psychology, 2013, 18, 1445-1455.	1.3	9
39	The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men. PLoS ONE, 2013, 8, e63619.	1.1	82
40	Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice. Dermatology, 2012, 225, 326-332.	0.9	45
41	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. Dermatology, 2012, 224, 236-243.	0.9	43
42	Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. British Journal of Dermatology, 2012, 166, 797-802.	1.4	54
43	Malignant melanoma: gender patterns in care seeking for suspect marks. Journal of Clinical Nursing, 2011, 20, 2676-2684.	1.4	25
44	Patientsâ€™ decision making in seeking care for suspected malignant melanoma. Journal of Nursing and Healthcare of Chronic Illness, 2010, 2, 164-173.	0.5	15
45	National Registries of Systemic Treatment for Psoriasis and the European â€˜Psonetâ€™ Initiative. Dermatology, 2009, 218, 347-356.	0.9	50
46	Switching Biologicals: Switching TNFÎ± Antagonists in Psoriasis Treatment. Dermatology, 2008, 216, 281-282.	0.9	2
47	PsoReg â€“ The Swedish Registry for Systemic Psoriasis Treatment. Dermatology, 2007, 214, 112-117.	0.9	47
48	EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families. BMC Medical Genetics, 2006, 7, 80.	2.1	29
49	Psoriasis Therapy in Real Life: The Need for Registries. Dermatology, 2006, 213, 327-330.	0.9	56
50	Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci. Experimental Dermatology, 2003, 12, 490-496.	1.4	26
51	Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. British Journal of Dermatology, 2003, 149, 381-385.	1.4	25
52	Association and Linkage of Human Leukocyte Antigens with Psoriasis â€“ Revisited. Transfusion Medicine and Hemotherapy, 2002, 29, 326-330.	0.7	4
53	Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. Tissue Antigens, 2001, 57, 440-446.	1.0	28
54	PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis. Clinical and Experimental Immunology, 2000, 119, 553-558.	1.1	22

#	Article	IF	Citations
55	Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13. American Journal of Human Genetics, 2000, 67, 1020-1024.	2.6	129
56	Promoter Polymorphism at â€“238 of the Tumor Necrosis Factor Alpha Gene is Not Associated with Early Onset Psoriasis when Tested by the Transmission Disequilibrium Test. Journal of Investigative Dermatology, 1999, 112, 514-515.	0.3	16
57	Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. Journal of Immunology, 1999, 163, 3250-9.	0.4	175
58	Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. British Journal of Dermatology, 1997, 136, 147-148.	1.4	65
59	Familial Juvenile Onset Psoriasis Is Associated with the Human Leukocyte Antigen (HLA) Class I side of the Extended Haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A Population- And Family-Based Study. Journal of Investigative Dermatology, 1996, 106, 711-714.	0.3	95
60	Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. Journal of Immunology, 1996, 157, 607-16.	0.4	232
61	Analysis of TAP2 and HLA-DP gene polymorphism in Psoriasis. Human Immunology, 1994, 40, 299-302.	1.2	18
62	Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. Journal of Rheumatology, 1994, 21, 665-9.	1.0	40
63	Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1*0701/2, -DQA* 0201, -DQB1*0303 Extended Haplotype. Journal of Investigative Dermatology, 1993, 100, 749-752.	0.3	71
64	Type I and Type II psoriasis Show a Similar Usage of T-Cell Receptor Variable Regions. Journal of Investigative Dermatology, 1991, 97, 1053-1056.	0.3	12